CJC-1295 / Ipamorelin Blend
CJC-1295/Ipamorelin is a combination of a growth hormone-releasing hormone (GHRH) analog and a growth hormone secretagogue peptide. Studied for synergistic effects on GH release and pulsatile secretion patterns.
≥99%
5mg/5mg
Lyophilized Powder
Store at -20°C. Protect from light and moisture.
Mechanism of Action
CJC-1295 is a synthetic 30-amino-acid analog of growth hormone-releasing hormone (GHRH) modified with a Drug Affinity Complex (DAC) that extends its half-life by binding to albumin. It activates the GHRH receptor on pituitary somatotrophs. Ipamorelin is a selective growth hormone secretagogue (GHS) that specifically activates the ghrelin receptor (GHS-R1a) without significant effects on cortisol, prolactin, or ACTH. Together, they produce synergistic, pulsatile growth hormone release through complementary GHRH and GHS receptor pathways.
Research Overview
The CJC-1295/Ipamorelin combination exploits two complementary growth hormone release mechanisms: GHRH receptor activation (CJC-1295) and ghrelin receptor activation (Ipamorelin). This dual-pathway approach has been studied for its ability to produce physiologically pulsatile GH secretion patterns rather than the sustained elevation caused by exogenous GH.
CJC-1295 was evaluated in clinical studies showing prolonged and sustained GH and IGF-1 elevation. A seminal 2006 study in the Journal of Clinical Endocrinology and Metabolism demonstrated that a single dose of CJC-1295 increased mean GH levels 2-10 fold for up to 6 days, with IGF-1 elevation of 1.5-3 fold lasting 9-11 days.
Ipamorelin was characterized as "the first selective growth hormone secretagogue" in a 1998 study, distinguishing it from earlier GH secretagogues that also stimulated cortisol and prolactin release. The selectivity of ipamorelin for GH release, combined with the sustained GHRH-receptor activation of CJC-1295, creates a research tool for studying clean, pulsatile GH secretion.
Published Research
Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I by CJC-1295, a long-acting GHRH analog
A single CJC-1295 dose produced 2-10 fold GH elevation for 6 days and 1.5-3 fold IGF-1 elevation for 9-11 days, demonstrating sustained somatotroph activation.
Ipamorelin selectively stimulates GH release via GHS-R1a without affecting cortisol, ACTH, or prolactin — the first GHS to demonstrate this selectivity.
Chemical Profile
| Sequence | CJC-1295: Modified GHRH(1-29) with DAC conjugation (30 aa). Ipamorelin: Aib-His-D-2Nal-D-Phe-Lys-NHâ‚‚ (5 aa pentapeptide) |
| Molecular Formula | Blend |
| Molecular Weight | Varies |
| CAS Number | 863288-34-0 / 170851-70-4 |
| Half-Life | CJC-1295 DAC: 6-8 days (albumin binding). Ipamorelin: ~2 hours (short-acting) |
| Solubility | Both soluble in bacteriostatic water at research concentrations |
| Bioavailability | Subcutaneous administration; CJC-1295 DAC provides sustained release via albumin binding |
Research Applications
References & Further Reading
- CJC-1295 — Wikipedia— Wikipedia
- Ipamorelin — Wikipedia— Wikipedia
- Growth Hormone Secretagogues — PMC Review— PMC / NIH
Research Use Only
This product is intended solely for laboratory research, analytical testing, and educational purposes. NOT FOR HUMAN CONSUMPTION. NOT FOR MEDICAL, VETERINARY, OR DIAGNOSTIC USE. This product has not been evaluated by the FDA.
